Movement Alert|BeOne Medicines Rises 3.01% in Regular Trading, Rebounding After Tax Payment Overhang Digested

Market Focus06-29

On June 29, BeOne Medicines rose 3.01% in regular trading, trading at approximately 171.5 HKD/share, with turnover of 246 million HKD.

On the news front, the stock is rebounding after the market rapidly digested a previously disclosed tax-related overhang. The company announced on June 26 that a wholly-owned domestic subsidiary received notice from local tax authorities to adjust prior tax filings, agreeing to pay additional income tax and late surcharges totaling approximately 446 million RMB. The A-share listed counterpart fell 4.37% on June 27 following the disclosure. The company explicitly stated that no administrative penalty is involved, the matter does not constitute a prior-period accounting error, and it is not expected to have a material adverse impact on financial position or ongoing operations. The supplemental tax amount is roughly equivalent to one month of first-quarter profit.

Additionally, the broader biotech sector rallied strongly, with AKESO up 8.1%, INNOVENT BIO up 5.39%, 3SBIO up 6.66%, and SKB BIO up 5.84%, providing sector-wide tailwinds for the rebound.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment